Defender Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Defender Capital’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-24,000	Closed	-$1.32M	–	37
2023 Q4	$1.32M	Hold	24,000	–	–	0.46%	16
2023 Q3	$1.39M	Hold	24,000	–	–	0.5%	15
2023 Q2	$1.29M	Hold	24,000	–	–	0.44%	15
2023 Q1	$953K	Hold	24,000	–	–	0.33%	18
2022 Q4	$966K	Hold	24,000	–	–	0.39%	15
2022 Q3	$712K	Hold	24,000	–	–	0.28%	20
2022 Q2	$712K	Hold	24,000	–	–	0.28%	19
2022 Q1	$675K	Buy	24,000 +5,000	+26%	+$186K	0.23%	20
2021 Q4	$876K	Hold	19,000	–	–	0.28%	19
2021 Q3	$624K	Hold	19,000	–	–	0.2%	27
2021 Q2	$665K	Hold	19,000	–	–	0.22%	24
2021 Q1	$687K	Buy	19,000 +4,000	+27%	+$125K	0.25%	25
2020 Q4	$436K	Buy	15,000 +5,000	+50%	+$143K	0.19%	23
2020 Q3	$282K	Buy	+10,000	New	+$298K	0.14%	24

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Defender Capital's ANIP Position: Q1 2024 in Review

Defender Capital sold out of ANI Pharmaceuticals (ANIP) in Q1 2024, closing a stake of 24,000 shares — an estimated $1.32M sold.

Defender Capital first reported a position in ANIP in Q3 2020 and held it in 14 quarters. The position peaked at $1.39M in Q3 2023. 199 funds tracked by Wall St. Rank hold ANIP as of Q1 2024.

Defender Capital reported no remaining ANI Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Defender Capital sold 24,000 ANI Pharmaceuticals shares in Q1 2024, an estimated $1.32M.
Defender Capital first reported a position in ANI Pharmaceuticals in Q3 2020 and held it in 14 quarters.
Defender Capital's ANI Pharmaceuticals position peaked at $1.39M in Q3 2023.
199 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2024.

Based on Defender Capital's 13F filing for Q1 2024, filed 6 May 2024.